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Abstract
Reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 2 237 leucine/methionine
(ND2-237 Leu/Met) polymorphism, is reportedly associated with longevity in the Japanese popu-
lation. The ND2-237Met genotype may exert resistance to atherogenic diseases, such as myocar-
dial infarction or cerebrovascular disorders. To investigate whether ND2-237 Leu/Met polymor-
phism is associated with yearly changes in serum lipid levels, we conducted a longitudinal study of
107 healthy Japanese male subjects. Analysis of covariance revealed that the interaction between
the ND2-237 Leu/Met genotypes and habitual drinking was significantly associated with yearly
changes in serum total cholesterol (TC) and low-density lipoprotein cholesterol (LDLC) levels
(p0.036 and p0.006, respectively). In multiple regression analysis, daily drinking was significantly
and positively associated with yearly changes in serum LDLC levels in men with ND2-237Met
(p0.026). After adjusting for covariates, yearly changes in serum LDLC levels were significantly
lower in non-daily drinkers with ND2-237Met than in those with ND2-237Leu (p0.047). These
results suggest that ND2-237Met has a beneficial impact on yearly changes in serum LDLC in
non-daily drinkers but not in daily drinkers.
KEYWORDS: daily alcohol consumption, longevity, total cholesterol, low-density lipoprotein
cholesterol, NADH dehydrogenase
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Reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase subunit 2 237 leucine/methionine 
(ND2-237 Leu/Met) polymorphism,  is reportedly associated with longevity in the Japanese population.  
The ND2-237Met genotype may exert resistance to atherogenic diseases,  such as myocardial infarction 
or cerebrovascular disorders.  To investigate whether ND2-237 Leu/Met polymorphism is associated 
with yearly changes in serum lipid levels,  we conducted a longitudinal study of 107 healthy Japanese 
male subjects.  Analysis of covariance revealed that the interaction between the ND2-237 Leu/Met 
genotypes and habitual drinking was signiﬁcantly associated with yearly changes in serum total choles-
terol (TC) and low-density lipoprotein cholesterol (LDLC) levels (p＝0.036 and p＝0.006,  respectively).  
In multiple regression analysis,  daily drinking was signiﬁcantly and positively associated with yearly 
changes in serum LDLC levels in men with ND2-237Met (p＝0.026).  After adjusting for covariates,  
yearly changes in serum LDLC levels were signiﬁcantly lower in non-daily drinkers with ND2-237Met 
than in those with ND2-237Leu (p＝0.047).  These results suggest that ND2-237Met has a beneﬁcial 
impact on yearly changes in serum LDLC in non-daily drinkers but not in daily drinkers.
Key words: daily alcohol consumption,  longevity,  total cholesterol,  low-density lipoprotein cholesterol,  
NADH dehydrogenase
itochondrial function is deeply associated with 
aging and longevity [1,  2].  Mitochondrial DNA 
cytosine/adenine (Mt5178 C/A) polymorphism,  which 
is also known as reduced nicotinamide adenine dinucle-
otide (NADH) dehydrogenase subunit-2 237 leucine/
methionine (ND2-237 Leu/Met) polymorphism,  is a 
longevity-associated mitochondrial DNA polymor-
phism [3-7].  The frequency of the ND2-237Met 
(Mt5178A) genotype is signiﬁcantly higher in Japanese 
centenarians than in the general population [3],  and it 
is reported that Japanese individuals with ND2-237Leu 
(Mt5178C) are more susceptible to lifestyle-related 
adult-onset diseases than those with ND2-237Met 
[8-11].  In addition,  the ND2-237Met genotype seems 
M
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to exert antiatherogenic eﬀects [12-14].  Previous 
reports have demonstrated that this polymorphism is 
associated with serum lipid levels,  such as high-den-
sity lipoprotein cholesterol (HDLC) levels and triglyc-
eride (TG) levels,  in Japanese subjects [12,  15].  
The ND2-237 Leu/Met polymorphism may interact 
with the eﬀects of daily drinking on serum TG levels,  
and may also interact with the eﬀects of habitual 
smoking on serum TG levels [15].  The relationship 
between healthy aging and lipidological properties has 
been epidemiologically discussed [16-18] and several 
vascular risk factors are reportedly associated with 
longevity [19].  Thus,  investigating the relationship 
between the longevity-associated ND2-237 Leu/Met 
polymorphism and serum lipid levels,  and especially 
yearly changes in serum lipid levels,  is useful for 
gerontological understanding and for the personalized 
prevention of lifestyle-related atherosclerotic diseases,  
such as myocardial infarction and cerebrovascular 
diseases.
　 The purpose of this study was to investigate the 
relationship between the longevity-associated ND2-237 
Leu/Met (Mt5178C/A) polymorphism and yearly 
changes in serum lipid levels,  and to also investigate 
the eﬀect of the interaction between the ND2-237 
Leu/Met polymorphism and habitual drinking or 
habitual smoking on serum lipid levels in healthy 
middle-aged Japanese male subjects.
Materials and Methods
　 Subjects. Participants were recruited from 
among individuals visiting the Mito Red Cross 
Hospital for regular medical check-ups in 1998 and/
or 1999.  Among these individuals,  110 male subjects 
who participated in health check-ups in both 1998 and 
1999 and who did not have any chronic disease or take 
any medication were enrolled in this study.  Three 
individuals with unclear drinking frequency were 
excluded.  Therefore,  the subjects comprised 107 
Japanese men (age,  55.0±6.9 years; mean±SD).  
This study was conducted in accordance with the 
Declaration of Helsinki and was approved by the 
Ethics Committee of Kyorin University School of 
Medicine.  Written informed consent was obtained 
from all volunteers before participation.
　 Clinical characteristics of subjects. The 
determination of blood chemical and physical data was 
conducted as described previously [12].  Brieﬂy,  
venous blood was drawn after a minimum fasting 
period of 12h.  Serum total cholesterol (TC) levels 
were measured by the Determiner L TC II (Kyowa 
Medex,  Tokyo,  Japan) [20],  serum HDLC levels by 
the Determiner L HDL-C (Kyowa Medex) [21],  and 
serum TG levels by the Determiner L TG II (Kyowa 
Medex) [22].  Serum low-density lipoprotein choles-
terol (LDLC) levels were calculated according to 
Friedewaldʼs formula [23].  Yearly changes in the 
TC,  HDLC,  LDLC,  and TG levels (ΔTC,  ΔHDLC,  
ΔLDLC,  and ΔTG) were calculated for each subject 
using the data obtained in 1998 and 1999.  Body mass 
index (BMI) was deﬁned as the ratio of subject weight 
(kg) to the square of subject height (m).  Yearly 
changes in BMI (ΔBMI) were also calculated for each 
subject using the data from 1998 and 1999.  A survey 
of drinking and smoking habits was performed by 
means of a questionnaire in 1999.  Habitual drinking 
was classiﬁed based on drinking frequency (daily 
drinkers; occasional drinkers,  which include those 
who drink several times per week; and non- or ex-
drinkers,  which include those who drink a few times 
per month).  Regarding habitual smoking,  individuals 
were classiﬁed as non- or ex-smokers and current 
smokers.
　 Genotyping. Genotyping methods were as 
described previously [12].  Brieﬂy,  DNA was 
extracted from white blood cells.  Polymerase chain 
reaction-restriction fragment length polymorphism 
using the restriction enzyme AluI was performed.  The 
absence of an AluI site was designated as ND2-237Met 
(Mt5178A),  and the presence of this restriction site 
was designated as ND2-237Leu (Mt5178C).
　 Statistical analyses. Statistical analyses were 
performed using SAS statistical software,  version 8.2 
for Windows (SAS Institute,  Inc.,  Cary,  NC,  USA,  
1999).  In the analysis of covariance and multiple 
regression analysis,  the ND2-237 Leu/Met genotypes 
(ND2-237Leu＝0,  ND2-237Met＝1),  habitual smok-
ing (non- or ex-smokers＝0,  current smokers＝1),  
and habitual drinking (non-/ex-/occasional-,  namely 
non-daily,  drinkers＝0,  daily-drinkers＝1) were 
numerically coded.  Serum lipid levels (1998),  age 
(1998),  BMI (1998),  and ΔBMI were included as 
covariates in the models.  Diﬀerences with p values of 
less than 0.05 were considered statistically signiﬁ-
cant.
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Results
　 Although one of the traits of inherence of mito-
chondrial DNA is heteroplasmy,  with respect to the 
Mt5178C/A (ND2-237 Leu/Met) polymorphism in 
subjects enrolled in this study,  no heteroplasmy was 
detected photographically.
　 No signiﬁcant diﬀerences in serum lipid character-
istics in 1998 or 1999 were observed between the 
ND2-237 Leu/Met genotypes (Table 1).  However,  
serum LDLC levels in 1998 tended to be higher in men 
with ND2-237Leu than in men with ND2-237Met (p＝
0.075),  and ΔHDLC was signiﬁcantly lower in men 
with ND2-237Met than in men with ND2-237Leu (p＝
0.005).
　 In the analysis of covariance (Table 2),  interac-
tions between the ND2-237 Leu/Met genotype and 
habitual drinking were signiﬁcantly associated with 
ΔTC and ΔLDLC (p＝0.036 and p＝0.006,  respec-
tively).  Serum lipid parameters in 1998 were signiﬁ-
cantly associated with yearly change in serum lipid 
levels (TC: p＝0.002,  HDLC: p＜0.001,  LDLC: p
＜0.001,  and TG: p＜0.001,  respectively).  Habitual 
smoking was signiﬁcantly associated with ΔTC (p＝
0.012).  Habitual drinking was signiﬁcantly associated 
with ΔHDLC and ΔTG (p＝0.013 and p＝0.008,  
respectively).  Age and BMI in 1998 were signiﬁcantly 
associated with ΔHDLC (p＝0.021 and p＜0.001,  
respectively).  ΔBMI was signiﬁcantly associated with 
ΔTC,  ΔHDLC and ΔLDLC (p＜0.001).
　 In multiple regression analysis for ΔTC and 
ΔLDLC (Table 3),  daily drinking was signiﬁcantly 
and positively associated with ΔLDLC in men with 
ND2-237Met (p＝0.026).  Daily drinking was posi-
tively associated with ΔTC in men with ND2-237Met 
(p＝0.063).  Habitual smoking was signiﬁcantly and 
positively associated with ΔTC only in men with ND2-
237Met (p＝0.009).  Serum TC levels (1998) were 
signiﬁcantly and negatively associated with ΔTC in 
men with ND2-237Met (p＜0.001).  ΔBMI was signiﬁ-
cantly and positively associated with ΔTC (ND2-237 
Leu: p＝0.036,  ND2-237Met: p＝0.003,  respec-
tively) and ΔLDLC (ND2-237Leu: p＝0.011,  ND2-
237Met: p＝0.005,  respectively).
　 After adjusting for age (1998),  BMI (1998),  
ΔBMI,  habitual smoking and serum lipid parameters 
(1998),  ΔHDLC was signiﬁcantly higher in daily 
drinkers with ND2-237Leu than in non-daily drinkers 
with ND2-237Leu (p＝0.015: Bonferroniʼs multiple 
comparison test) (Table 4).  ΔLDLC was signiﬁcantly 
lower in non-daily drinkers with ND2-237Met than in 
those with ND2-237Leu (p＝0.047: Bonferroniʼs 
multiple comparison test).  In all subjects with the 
ND2-237Met genotype,  after adjustment,  ΔTC and 
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Table 1　 Serum lipid levels in 1998 and 1999 and yearly changes
ND2-237Leu (N＝64) ND2-237Met (N＝43) P value
Age (1998) 55.8±0.9 53.8±1.0 0.144
BMI (1998) 22.9±0.3 23.3±0.4 0.529
BMI (1999) 22.9±0.3 23.4±0.4 0.374
ΔBMI －0.03±0.07 0.10±0.09 0.249
TC (1998) 201.7±4.1 195.3±5.0 0.330
TC (1999) 204.5±4.2 194.5±5.0 0.138
ΔTC 2.8±2.4 －0.8±3.0 0.591
HDLC (1998) 54.8±2.0 59.7±5.0 0.122
HDLC (1999) 54.5±1.7 55.4±2.2 0.697
ΔHDLC －0.3±1.0 －4.3±1.1 0.005
LDLC (1998) 119.6±3.9 108.4±4.8 0.075
LDLC (1999) 124.4±4.0 114.3±4.7 0.109
ΔLDLC 4.8±2.5 5.9±3.1 0.792
TG (1998) 136.7±9.4 136.0±11.5 0.965
TG (1999) 128.4±7.9 132.3±9.6 0.802
ΔTG －8.3±6.9 －3.7±8.4 0.671
Age, body mass index (BMI),  serum total cholesterol (TC),  serum high-density lipoprotein cholesterol (HDLC),  serum low-density lipopro-
tein cholesterol (LDLC),  serum triglyceride (TG) and yearly changes (ΔBMI,  ΔTC,  ΔHDLC,  ΔLDLC,  and ΔTG) are given as means±S.E.  
All P values depict the signiﬁcance of diﬀerences between ND2-237Leu and ND2-237Met.
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ΔLDLC were positive; however,  in non-daily drink-
ers with the ND2-237Met genotype,  ΔTC and ΔLDLC 
were negative.
Discussion
　 The present study demonstrates the eﬀect of inter-
actions between the ND2-237 Leu/Met (Mt5178C/A) 
polymorphism and frequency of alcohol consumption on 
yearly changes in serum TC and LDLC levels.  
Overall,  after adjustment,  serum TC and LDLC 
levels increased from 1998 to 1999; however,  in non-
daily drinkers with the ND2-237Met (antiatherogenic) 
genotype,  serum TC and LDLC levels decreased 
334 Acta Med.  Okayama　Vol.  63,  No.  6Makita et al.
Table 2　 Analysis of covariance for yearly changes in serum lipid levels
ΔTC ΔHDLC ΔLDLC ΔTG
TC (1998)  9.96＊＊＊
HDLC (1998) 57.7＊＊＊＊
LDLC (1998) 15.95＊＊＊＊
TG (1998) 57.1＊＊＊＊
ND2-237 Leu/Met genotype  1.25  3.65  0.31 0.03
Habitual smoking  6.51＊  0.13  3.87 1.24
Habitual drinking  0.09  6.41＊  0.22 7.26＊＊
ND2-237 Leu/Met genotype
×Habitual smoking  0.91  0.41  0.87 0.00
ND2-237 Leu/Met genotype
×Habitual drinking  4.54
＊  3.27  8.06＊＊ 0.34
Age (1998)  0.03  5.50＊  1.65 0.23
BMI (1998)  0.00 12.0＊＊＊＊  0.38 2.21
ΔBMI 13.1＊＊＊＊ 14.0＊＊＊＊ 17.8＊＊＊＊ 1.93
Values are F values.  ＊p＜0.05,  ＊＊p＜0.01,  ＊＊＊p＜0.005,  ＊＊＊＊p＜0.001.  In analysis,  some independent variables were numerically 
coded: ND2-237 Leu/Met genotypes (Leu＝0,  Met＝1),  habitual smoking (non- or ex-smokers＝0,  current smokers＝1),  and habitual 
drinking (non-daily drinkers＝0,  daily drinkers＝1).  ND2-237 Leu/Met genotype×habitual smoking represents the interaction between 
ND2-237 Leu/Met and habitual smoking.  ND2-237 Leu/Met genotype×habitual drinking represents the interaction between ND2-237 
Leu/Met and habitual drinking.
BMI,  body mass index; TC,  serum total cholesterol; HDLC,  serum high-density lipoprotein cholesterol; LDLC,  serum low-density lipopro-
tein cholesterol; TG,  serum triglyceride; ΔBMI,  yearly changes in body mass index; ΔTC,  yearly change in serum total cholesterol;
ΔHDLC,  yearly changes in serum high-density lipoprotein cholesterol; ΔLDLC,  yearly changes in serum low-density lipoprotein choles-
terol; ΔTG,  yearly changes in serum triglyceride.
Table 3　 Multiple regression analysis for yearly changes in serum TC and LDLC levels
ΔTC ΔLDLC
ND2-237Leu ND2-237Met ND2-237Leu ND2-237Met
TC (1998) －0.113 －0.290＊＊＊＊
LDLC (1998) －0.167＊ －0.376＊＊＊
Habitual smoking 6.437 12.52＊＊ 3.915 9.644
Habitual drinking －6.924 8.401 －5.093 13.93＊
Age (1998) －0.053 0.203 －0.005 0.722
BMI (1998) －0.068 0.003 －0.065 1.013
ΔBMI 11.70＊ 10.85＊＊＊ 13.06＊ 12.58＊＊＊
Values are partial regression coeﬃcients.  ＊p＜0.05,  ＊＊p＜0.01,  ＊＊＊p＜0.005,  ＊＊＊＊p＜0.001.  In multiple regression analysis,  some 
independent variables were numerically coded: habitual smoking (non- or ex-smokers＝0,  current smokers＝1),  and habitual drinking 
(non-daily drinkers＝0,  daily drinkers＝1).
BMI,  body mass index; TC,  serum total cholesterol; LDLC,  serum low-density lipoprotein cholesterol; ΔBMI,  yearly changes in body 
mass index; ΔTC,  yearly changes in serum total cholesterol; ΔLDLC,  yearly changes in serum low-density lipoprotein cholesterol.
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from 1998 to 1999.
　 Individuals with the ND2-237Leu genotype may be 
more susceptible to lifestyle-related adult-onset dis-
eases,  such as myocardial infarction [8,  9],  cerebro-
vascular diseases [10],  and type 2 diabetes [11],  
than individuals with ND2-237Met.  Ultrasonography 
revealed that the mean intima-media thickness in the 
bilateral carotid arteries is signiﬁcantly greater in 
type 2 diabetic patients with the ND2-237Leu geno-
type than in those with the ND2-237Met genotype 
[14].  In healthy men,  after adjusting for age and 
BMI,  serum HDLC levels were signiﬁcantly higher in 
men with the ND2-237Met genotype than in those with 
the ND2-237Leu genotype [12].  Low levels of HDLC 
are a risk factor for atherosclerotic diseases [24,  
25],  while high levels of LDLC are epidemi ologically 
and clinically known to be a crucial risk factor for 
atherosclerotic diseases [26,  27].  The ND2-237 
Leu/Met polymorphism,  which may interact with 
habitual drinking in aﬀecting yearly changes in serum 
LDLC levels,  appears to be a longevity-associated 
vascular genetic factor [19].
　 We previously reported that the ND2-237 Leu/Met 
polymorphism inﬂuences the eﬀects of alcohol con-
sumption on blood pressure [28,  29],  serum TG 
levels [15],  fasting plasma glucose (FPG) levels and 
response to a 75-g oral glucose tolerance test [30],  
serum uric acid levels [31] and intraocular pressure 
[32],  as well as the eﬀects of cigarette smoking on 
serum TG levels [15],  red blood cell counts [33],  
intraocular pressure [32],  pulmonary function [34],  
and serum protein fraction levels [13].  The amino 
acid change from leucine to methionine at residue 237 
of NADH dehydrogenase subunit 2 may bring about a 
functional change in NADH dehydrogenase.  NADH 
dehydrogenase is involved in the production of reactive 
oxygen species (ROS) [35].  Moreover,  habitual 
drinking stimulates the production of ROS by NADH 
dehydrogenase [36],  and chronic ethanol consumption 
increases the susceptibility of mitochondrial proteins,  
including NADH dehydrogenase,  to ROS [37].  We 
believe that diﬀerences in ethanol-related ROS pro-
duction and/or ROS sensitivity between ND2-237 
Leu/Met result in diﬀerences in yearly changes in 
serum lipid levels.  Based on an investigation showing 
that cigarette smoking attenuates the activity of 
NADH dehydrogenase [38],  we postulated that there 
are unidentiﬁed diﬀerences in smoking-related ROS 
production and/or ROS sensitivity between ND2-237 
Leu/Met [13,  15,  32,  33].  However,  in the present 
study,  no interaction between the ND2-237 Leu/Met 
polymorphism and habitual smoking was observed with 
regard to yearly changes in serum lipid levels (Table 
2).  In any case,  to elucidate the mechanisms of the 
biophysical and biochemical diﬀerences between the 
ND2-237 Leu/Met genotypes [12,  13,  15,  28-33,  
39],  further investigation is required.
　 With regard to yearly changes in serum TC and 
LDLC levels (Table 3),  weight gain is apparently 
disadvantageous for both ND2-237Leu genotypic men 
and ND2-237Met genotypic men.  We previously 
reported that in men with a BMI＜22,  FPG levels 
were signiﬁcantly lower in the antiatherogenic ND2-
237Met genotype than in the ND2-237Leu genotype 
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Table 4　 Comparisons of yearly changes in serum lipid levels between non-daily drinkers and daily drinkers by ND2-237 Leu/Met geno-
type (adjusted)
ND2-237Leu ND2-237Met
Non-daily
drinkers
(N＝20)
Daily drinkers
(N＝44)
Total
(N＝64)
Non-daily
drinkers
(N＝14)
Daily drinkers
(N＝29)
Total
(N＝43)
ΔTC 9.2±4.0 1.6±2.7 4.2±2.3 －5.4±4.8 3.1±3.3 0.6±2.9
ΔHDLC －4.4±1.3 0.5±0.8＊ －1.6±0.8 －3.5±1.5 －3.0±1.1 －3.2±0.9
ΔLDLC 11.4±4.1 4.2±2.7 6.0±2.4 －5.4±4.5＊ 9.3±3.0 4.3±2.8
ΔTG 7.4±9.9 －13.2±6.7 －2.1±5.7 16.5±12.0 －15.1±8.3 －0.5±7.0
Yearly changes in serum total cholesterol (ΔTC),  yearly changes in serum high-density lipoprotein cholesterol (ΔHDLC),  yearly changes in 
serum low-density lipoprotein cholesterol (ΔLDLC) and yearly changes in serum triglyceride (ΔTG) are given as means±S.E.  (mg/dl) 
adjusted for age (1998),  BMI (1998),  ΔBMI,  habitual smoking,  and serum lipid parameters (1998).  Non-daily drinkers were deﬁned as 
ʻnever or seldomʼ,  ʻseveral times per monthʼ,  or ʻseveral times per weekʼ drinkers.  Bonferroni correction for multiple comparisons was 
applied.  ＊p＜0.05 vs.  non-daily drinkers with ND2-237Leu.
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[30].  However,  in men with a BMIｧ22,  FPG levels 
were signiﬁcantly higher in the ND2-237Met genotype 
than in the ND2-237Leu genotype.  Therefore,  gaining 
weight or becoming overweight may counteract the 
genetic merits of the longevity-associated ND2-
237Met genotype.
　 Alcohol intake interacts with the eﬀects of the 
apolipoprotein E gene polymorphism on serum lipid 
levels [40,  41].  Several genetic polymorphisms are 
associated with serum TC or LDLC levels [42-45].  
Moreover,  the eﬀects of several gene-diet interactions 
on lipid metabolism have also been reported [46-48].  
Therefore,  further investigations of gene-gene or 
gene-gene-environment interactions,  and their eﬀects 
on serum lipid levels,  are needed to elucidate the 
mechanisms of lipid metabolism.
　 Larger decreases in HDLC levels were seen in men 
with antiatherogenic ND2-237Met than in those with 
ND2-237Leu (Table 1).  This may be a ʻregression to 
the meanʼ eﬀect,  namely the phenomenon that a vari-
able that is extreme on its ﬁrst measurement will tend 
to be closer to the center of the distribution at later 
measurements [49].  Takashima et al.  suggested the 
necessity of allowing the ʻregression to the meanʼ eﬀect 
for accurate evaluation of yearly changes in serum 
lipid levels [50].  In our studies,  after considering the 
baseline data for serum lipid levels as covariates,  the 
eﬀects of interactions between longevity-associated 
ND2-237 Leu/Met polymorphism and daily alcohol 
drinking on yearly changes in serum TC and LDLC 
levels were observed.
　 This study had several limitations,  including a 
small number of subjects,  a lack of dietary informa-
tion,  and a lack of information regarding lifestyle 
disorders immediately prior to medical check-ups.  In 
addition,  the evaluation of habitual drinking was based 
on the frequency of alcohol consumption.  Although we 
have used this type of evaluation in previous reports 
[15,  28-32],  further investigation into the eﬀect of 
interactions between Mt5178C/A polymorphism and 
volume of alcohol intake on yearly changes of serum 
lipid levels is warranted.  Moreover,  we examined only 
yearly changes in lipid levels in this study.  Therefore,  
further investigations of longer-term changes in lipid 
levels between Mt5178C/A genotypes are required.
　 In conclusion,  ND2-237Met (Mt5178A) may have 
a beneﬁcial impact on yearly changes in serum LDLC 
levels in non-daily drinkers but not in daily drinkers.  
A decrease in LDLC levels was observed in non-
drinkers with ND2-237Met.  Non-daily drinking may 
exert an antiatherogenic advantage in men with the 
longevity-associated mitochondrial DNA genotype.  
These ﬁndings may contribute to the establishment of 
personalized primary and secondary prevention of 
hyperlipidemia and to lowering the incidence of myo-
cardial infarction and cerebrovascular diseases.
Acknowledgments.　This study was supported in part by Grants-in-
Aid from the Ministry of Education,  Culture,  Sports,  Science and 
Technology of Japan (No. 14570355 and No. 18590572) and the Chiyoda 
Mutual Life Foundation.
References
 1. Van Remmen H and Richardson A: Oxidative damage to mitochon-
dria and aging.  Exp Gerontol (2001) 36: 957-968.
 2. Driver C: Mitochondrial interventions in aging and longevity; in 
Biology of aging and its modulation vol. 5: Modulating aging and 
longevity,  Rattan SIS ed,  Kluwer Academic Publishers,  Dordrecht 
(2003) pp 205-217.
 3. Tanaka M,  Gong J-S,  Zhang J,  Yoneda M and Yagi K: Mitochondrial 
genotype associated with longevity.  Lancet (1998) 351: 185-186.
 4. Ivanova R,  Lepage V,  Charron D and Schächter F: Mitochondrial 
genotype associated with French Caucasian centenarians.  Geron-
tology (1998) 44: 349.
 5. De Benedictis G,  Rose G,  Carrieri G,  De Luca M,  Falcone E,  
Passarino G,  Bonafé M,  Monti D,  Baggio G,  Bertolini S,  Mari D,  
Mattace R and Franceschi C: Mitochondrial DNA inherited vari-
ants are associated with successful aging and longevity in humans.  
FASEB J (1999) 13: 1532-1536.
 6. Ross OA,  McCormack R,  Curran MD,  Duguid RA,  Barnett YA,  
Rea IM and Middleton D: Mitochondrial DNA polymorphism: its 
role in longevity of the Irish population.  Exp Gerontol (2001) 36:  
1161-1178.
 7. Niemi AK,  Moilanen JS,  Tanaka M,  Hervonen A,  Hurme M,  
Lehtimaki T,  Arai Y,  Hirose N and Majamaa K: A combination of 
three common inherited mitochondrial DNA polymorphisms pro-
motes longevity in Finnish and Japanese subjects.  Eur J Hum 
Genet (2005) 13: 166-170.
 8. Mukae S,  Aoki S,  Itoh S,  Satoh R,  Nishio K,  Iwata T and Katagiri 
T: Mitochondrial 5178A/C genotype is associated with acute 
myocardial infarction.  Circ J (2003) 67: 16-20.
 9. Takagi K,  Yamada Y,  Gong J-S,  Sone T,  Yokota M and Tanaka M:  
Association of a 5178C→A (Leu237Met) polymorphism in the 
mitochondrial DNA with a low prevalence of myocardial infarction 
in Japanese individuals.  Atherosclerosis (2004) 175: 281-286.
10. Ohkubo R,  Nakagawa M,  Ikeda K,  Kodama T,  Arimura K,  Akiba S,  
Saito M,  Ookatsu Y,  Atsuchi Y,  Yamano Y and Osame M:  
Cerebrovascular disorders and genetic polymorphisms: mitochon-
drial DNA5178C is predominant in cerebrovascular disorders.  J 
Neurol Sci (2002) 198: 31-35.
11. Wang D,  Taniyama M,  Suzuki Y,  Katagiri T and Ban Y: Association 
of the mitochondrial DNA 5178A/C polymorphism with maternal 
inheritance and onset of type 2 diabetes in Japanese patients.  Exp 
Clin Endocrinol Diabetes (2001) 109: 361-364.
12. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Sekine Y,  
336 Acta Med.  Okayama　Vol.  63,  No.  6Makita et al.
6
Acta Medica Okayama, Vol. 63 [2009], Iss. 6, Art. 4
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss6/4
Teruya K,  Takeda N,  Sumiya Y,  Uchida Y and Takashima Y:  
Association of the mitochondrial DNA 5178A/C polymorphism with 
serum lipid levels in the Japanese population.  Hum Genet (2001) 
109: 521-525.
13. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Sekine Y,  
Sekiguchi K,  Satoh M,  Harada M,  Teruya K,  Takeda N,  Uchida 
Y and Takashima Y: Longevity-associated mitochondrial DNA 
5178A/C polymorphism inﬂuences eﬀects of cigarette smoking on 
serum protein fraction levels in Japanese men.  Mech Ageing Dev 
(2003) 124: 765-770.
14. Matsunaga H,  Tanaka Y,  Tanaka M,  Gong JS,  Zhang J,  
Nomiyama T,  Ogawa O,  Ogihara T,  Yamada Y,  Yagi K and 
Kawamori R: Antiatherogenic mitochondrial genotype in patients 
with type 2 diabetes.  Diabetes Care (2001) 24: 500-503.
15. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Sekine Y,  
Sekiguchi K,  Satoh M,  Harada M,  Teruya K,  Takeda N,  Uchida Y,  
Tsunoda T and Takashima Y: Longevity-associated mitochondrial 
DNA 5178A/C polymorphism modulates eﬀects of daily drinking 
and cigarette consumption on serum triglyceride levels in middle-
aged Japanese men.  Exp Gerontol (2003) 38: 1071-1076.
16. Shepherd J: Issues surrounding age: vascular disease in the 
elderly.  Curr Opin Lipidol (2001) 12: 601-609.
17. Arai Y and Hirose N: Aging and HDL metabolism in elderly people 
more than 100 years old.  J Atheroscler Thromb (2004) 11: 246-
252.
18. Atzmon G,  Rincon M,  Rabizadeh P and Barzilai N: Biological evi-
dence for inheritance of exceptional longevity.  Mech Ageing Dev 
(2005) 126: 341-345.
19. Panza F,  DʼIntrono A,  Colacicco AM,  Capurso C,  Capurso S,  
Kehoe PG,  Capurso A and Solfrizzi V: Vascular genetic factors 
and human longevity.  Mech Ageing Dev (2004) 125: 169-178.
20. Allain CC,  Poon LS,  Chan CS,  Richmond W and Fu PC:  
Enzymatic determination of total serum cholesterol.  Clin Chem 
(1974) 20: 470-475.
21. Sugiuchi H,  Uji Y,  Okabe H,  Irie T,  Uekama K,  Kayahara N and 
Miyauchi K: Direct measurement of high-density lipoprotein cho-
lesterol in serum with polyethylene glycol-modiﬁed enzymes and 
sulfated alpha-cyclodextrin.  Clin Chem (1995) 41: 717-723.
22. Fossati P and Prencipe L: Serum triglyceride determined colori-
metrically with an enzyme that produces hydrogen peroxide.  Clin 
Chem (1982) 28: 2077-2080.
23. Friedewald WT,  Levy RI and Fredrickson DS: Estimation of the 
concentration of low-density lipoprotein cholesterol in plasma,  
without use of the preparative ultracentrifuge.  Clin Chem (1972) 
18: 499-502.
24. Goldbourt U,  Yaari S and Medalie JH: Isolated low HDL choles-
terol as a risk factor for coronary heart disease mortality.  A 21-year 
follow-up of 8000 men.  Arterioscler Thromb Vasc Biol (1997) 17:  
107-113.
25. Wannamethee SG,  Shaper AG and Ebrahim S: HDL-cholesterol,  
total cholesterol,  and the risk of stroke in middle-aged British men.  
Stroke (2000) 31: 1882-1888.
26. Tegos TJ,  Kalodiki E,  Sabetai MM and Nicolaides AN: The gene-
sis of atherosclerosis and risk factors: a review.  Angiology (2001) 
52: 89-98.
27. Grundy SM,  Cleeman JI,  Merz CN,  Brewer HB Jr,  Clarl LT,  
Hunninghake DB,  Pasternak RC,  Smith SC Jr,  Stone NJ and 
National Heart,  Lung,  and Blood Institute,  American College of 
cardiology Foundation,  and American Heart Association:  
Implications of recent clinical trails for the National Cholesterol 
Education Program Adult Treatment Panel III guidelines.  Circula-
tion (2004) 110: 227-239.
28. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Sekine Y,  
Sekiguchi K,  Harada M,  Satoh M,  Teruya K,  Takeda N,  
Fukazawa S,  Uchida Y and Takashima Y: Longevity-associated 
mitochondrial DNA 5178A/C polymorphism and blood pressure in 
the Japanese population.  J Hum Hypertens (2004) 18: 41-45.
29. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Satoh M,  
Teruya K,  Honmyo R,  Masuda Y,  Uchida Y and Takashima Y:  
NADH dehydrogenase subunit-2 237 Leu/Met polymorphism modi-
ﬁes the eﬀects of alcohol consumption on risk for hypertension in 
middle-aged Japanese men.  Hypertens Res (2007) 30: 213-218.
30. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Makita R,  
Satoh M,  Teruya K,  Sekiguchi K,  Masuda Y,  Harada M,  Uchida 
Y and Takashima Y: Longevity-associated mitochondrial DNA 
5178C/A polymorphism is associated with fasting plasma glucose 
levels and glucose tolerance in Japanese men.  Mitochondrion 
(2005) 5: 418-425.
31. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Satoh M,  
Teruya K,  Honmyo R,  Yorimitsu M,  Masuda Y,  Uchida Y and 
Takashima Y: Longevity-associated NADH dehydrogenase sub-
unit-2 237 Leu/Met polymorphism inﬂuences the eﬀects of alcohol 
consumption on serum uric acid levels in nonobese Japanese men.  
J Hum Genet (2006) 51: 765-771.
32. Kokaze A,  Yoshida M,  Ishikawa M,  Matsunaga N,  Makita R,  
Satoh M,  Sekiguchi K,  Matsuda Y,  Uchida Y and Takashima Y:  
Longevity-associated mitochondrial DNA 5178A/C polymorphism 
is associated with intraocular pressure in Japanese men.  Clin 
Experiment Ophthalmol (2004) 32: 131-136.
33. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Makita R,  
Satoh M,  Teruya K,  Sekiguchi K,  Masuda Y,  Harada M,  Uchida 
Y and Takashima Y: Interaction between longevity-associated 
mitochondrial DNA 5178C/A polymorphism and cigarette smoking 
on hematological parameters in Japanese men.  Arch Gerontol 
Geriatr (2005) 40: 113-122.
34. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Satoh M,  
Teruya K,  Honmyo R,  Shirasawa T,  Hoshino H and Takashima Y:  
Longevity-associated mitochondrial DNA 5178C/A polymorphism 
and its interaction with cigarette consumption are associated with 
pulmonary function in middle-aged Japanese men.  J Hum Genet 
(2007) 52: 680-685.
35. Lenaz G,  Bovina C,  Aurelio MDʼ,  Fato R,  Formiggini G,  Genova 
ML,  Giuliano G,  Merlo-Pich M,  Paolucci U,  Parenti Castelli G 
and Ventura B: Role of Mitochondria in oxidative stress and aging.  
Ann NY Acad Sci (2002) 959: 199-213.
36. Bailey SM,  Pietsch EC and Cunningham CC: Ethanol stimulates 
the production of reactive oxygen species at mitochondrial complex 
I and III.  Free Radic Biol Med (1999) 27: 891-900.
37. Bailey SM and Cunningham CC: Contribution of mitochondria to 
oxidative stress associated with alcoholic liver disease.  Free 
Radic Biol Med (2002) 32: 11-16.
38. Smith PR,  Cooper JM,  Govan GG,  Harding AE and Scapira AH:  
Smoking and mitochondrial function: a model for environmental 
toxins.  Q J Med (1993) 86: 657-660.
39. Kokaze A,  Ishikawa M,  Matsunaga N,  Yoshida M,  Makita R,  
Satoh M,  Teruya K,  Sekiguchi K,  Masuda Y,  Harada M,  Uchida 
Y and Takashima Y: Longevity-associated NADH dehydrogenase 
subunit-2 polymorphism and serum electrolyte levels in middle-
aged obese Japanese men.  Mech Ageing Dev (2005) 126: 705-
709.
40. Corella D,  Tucker K,  Lahoz C,  Coltell O,  Cupples LA,  Wilson 
WF,  Schaefer EJ and Ordovas JM: Alcohol drinking determines 
337ND2-237 Leu/Met Genotype and Serum LipidDecember 2009
7
Makita et al.: Longevity-associated NADH Dehydrogenase Subunit-2 237 Leu/Met Pol
Produced by The Berkeley Electronic Press, 2009
the eﬀect of the APOE locus on LDL-cholesterol concentrations in 
men: the Framingham Oﬀspring Study.  Am J Clin Nutr (2001) 73:  
736-745.
41. Corella D,  Guillén M,  Sáiz C,  Portolés O,  Sabater A,  Cortina S,  
Folch J,  González JI and Ordovas M: Environmental factors modu-
late the eﬀect of the APOE genetic polymorphism on plasma lipid 
concentrations: Ecogenetic studies in a Mediterranean Spanish 
population.  Metabolism (2001) 50: 936-944.
42. Bentzen J,  Jørgensen T and Fenger M: The eﬀect of six polymor-
phisms in the apolipoprotein B gene on parameters of lipid metabo-
lism in a Danish population.  Clin Genet (2002) 61: 126-134.
43. Galluzzi JR,  Cupples LA,  Otvos JD,  Wilson PW,  Schaefer EJ and 
Ordovas JM: Association of the A/T54 polymorphism in the intes-
tinal fatty acid binding protein with variations in plasma lipids in 
The Framingham Oﬀspring Study.  Atherosclerosis (2001) 159:  
417-424.
44. Tai ES,  Demissie S,  Cupples LA,  Corella D,  Wilson PW,  
Schaefer EJ and Ordovas JM: Association between the PPARA 
L162V polymorphism and plasma lipid levels.  The Framingham 
Oﬀspring Study.  Arterioscler Thromb Vasc Biol (2002) 22: 805-
810.
45. Benn M,  Nordestgaard BG,  Jensen JS,  Grande P,  Sillesen H and 
Tybjaerg-Hansen A: Polymorphism in APOB associated with 
increased low-density lipoprotein levels in both genders in the gen-
eral population.  J Clin Endocrinol Metab (2005) 90: 5797-5803.
46. Ordovas JM: Gene-diet interaction and plasma lipid responses to 
dietary intervention.  Biochem Soc Trans (2002) 30: 68-73.
47. Vincent S,  Planells R,  Defoort C,  Bernard MC,  Gerber M,  
Prudhomme J,  Vague P and Lairon D: Genetic polymorphisms and 
lipoprotein responses to diets.  Proc Nutr Soc (2002) 61: 427-434.
48. Weinberg RB: Apolipoprotein A-IV polymorphisms and diet-gene 
interactions.  Curr Opin Lipidol (2002) 13: 125-134.
49. Everitt BS: Medical statistics from A to Z 2nd Ed,  Cambridge 
University Press,  Cambridge (2006) p 198.
50. Takashima Y,  Sumiya Y,  Kokaze A,  Yoshida M,  Ishikawa M,  
Sekine Y and Akamatsu S: Magnitude of the regression to the 
mean within one-year intra-individual changes in serum lipid levels 
among Japanese male workers.  J Epidemiol (2001) 11: 61-69.
338 Acta Med.  Okayama　Vol.  63,  No.  6Makita et al.
8
Acta Medica Okayama, Vol. 63 [2009], Iss. 6, Art. 4
http://escholarship.lib.okayama-u.ac.jp/amo/vol63/iss6/4
